Advertisement

Persistence in Percutaneous Tibial Nerve Stimulation Treatment for Overactive Bladder Syndrome is Best Predicted by Patient Global Impression of Improvement Rather Than Symptom-Specific Improvement

Published:December 21, 2020DOI:https://doi.org/10.1016/j.urology.2020.12.009

      OBJECTIVES

      To evaluate whether progression to maintenance percutaneous tibial nerve stimulation (PTNS) was related to perceived global impression of improvement (PGII) rather than symptom-specific improvement in patient with overactive bladder (OAB). We hypothesize that PGII will predict continuation of PTNS long-term.

      METHODS

      This prospective observational study included 90 patients with OAB that initiated PTNS. The PGII and OAB short-form questionnaires (OABq-SF) were used to assess bladder symptom severity and improvement. Those that completed the 12-week induction phase were offered to continue PTNS monthly maintenance or pursue other options. The primary outcome was difference in PGII score between those pursuing maintenance therapy versus other options. Descriptive statistics and mixed effect modeling analysis were employed.

      RESULTS

      Seventy patients (78%) completed 12 weeks of PTNS. The majority of completers pursued monthly maintenance (P< .01) and had significantly lower median PGII scores compared with those who sought alternatives (P < .01), while OABq-SF scores did not differ significantly (P = .65). Patients that pursued monthly PTNS maintenance had lower body mass index than those who chose alternative therapies (P < .01). Only 19% continued PTNS therapy for at least 1 year.

      CONCLUSION

      More patients pursued PTNS monthly maintenance over any other therapy, and this was significantly associated with lower PGII scores. Global improvement, and not symptom-specific response, predicts long-term PTNS maintenance. No symptom-specific predictors were identified in those who pursued maintenance over other options. One-year continuation rates are low.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Haylen BT
        • de Ridder D
        • Freeman RM
        • et al.
        An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction.
        Int Urogynecol J. 2010; 21 (2009/11/26): 5-26https://doi.org/10.1007/s00192-009-0976-9
        • Moossdorff-Steinhauser HF
        • Berghmans B.
        Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review.
        Neurourol Urodyn. 2013; 32 (2012/08/22): 206-214https://doi.org/10.1002/nau.22296
        • Stewart WF
        • Van Rooyen JB
        • Cundiff GW
        • et al.
        Prevalence and burden of overactive bladder in the United States.
        World J Urol. 2003; 20 (2003/06/18): 327-336https://doi.org/10.1007/s00345-002-0301-4
        • Lightner DJ
        • Gomelsky A
        • Souter L
        • et al.
        Diagnosis and treatment of overactive bladder (Non-Neurogenic) in adults: AUA/SUFU guideline amendment 2019.
        J Urol. 2019; 202 (2019/05/01): 558-563https://doi.org/10.1097/ju.0000000000000309
        • Sicras-Mainar A
        • Rejas J
        • Navarro-Artieda R
        • et al.
        Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.
        Int Urogynecol J. 2014; 25 (2013/11/08): 485-492https://doi.org/10.1007/s00192-013-2250-4
        • Govier FE
        • Litwiller S
        • Nitti V
        • et al.
        Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study.
        J Urol. 2001; 165 (2001/03/21): 1193-1198
        • Peters KM
        • Carrico DJ
        • Perez-Marrero RA
        • et al.
        Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial.
        J Urol. 2010; 183 (2010/02/23): 1438-1443https://doi.org/10.1016/j.juro.2009.12.036
        • Peters KM
        • Carrico DJ
        • Wooldridge LS
        • et al.
        Percutaneous tibial nerve stimulation for the long-term treatment of overactive bladder: 3-year results of the STEP study.
        J Urol. 2013; 189 (2012/12/12): 2194-2201https://doi.org/10.1016/j.juro.2012.11.175
        • Peters KM
        • Macdiarmid SA
        • Wooldridge LS
        • et al.
        Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine; results from the overactive bladder innovative therapy trial.
        J Urol. 2009; 182 (2009/07/21): 1055-1061https://doi.org/10.1016/j.juro.2009.05.045
        • Peters KM
        • Carrico DJ
        • MacDiarmid SA
        • et al.
        Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study.
        Neurourol Urodyn. 2013; 32 (2012/06/08): 24-29https://doi.org/10.1002/nau.22266
        • Yoong W
        • Shah P
        • Dadswell R
        • et al.
        Sustained effectiveness of percutaneous tibial nerve stimulation for overactive bladder syndrome: 2-year follow-up of positive responders.
        Int Urogynecol J. 2013; 24 (2012/09/08): 795-799https://doi.org/10.1007/s00192-012-1936-3
        • Te Dorsthorst MJ
        • Heesakkers J
        • van Balken MR
        Long-term real-life adherence of percutaneous tibial nerve stimulation in over 400 patients.
        Neurourol Urodyn. 2020; 39 (2019/12/18): 702-706https://doi.org/10.1002/nau.24254
        • Salatzki J
        • Liechti MD
        • Spanudakis E
        • et al.
        Factors influencing return for maintenance treatment with percutaneous tibial nerve stimulation for the management of the overactive bladder.
        BJU Int. 2019; 123 (2018/12/16): E20-e28https://doi.org/10.1111/bju.14651
        • Pincus J
        • Rostaminia G
        • Chang C
        • et al.
        Factors associated with overactive bladder symptom improvement after 1 year of monthly percutaneous tibial nerve stimulation therapy.
        Neurourol Urodyn. 2019; 38 (2019/05/21): 1676-1684https://doi.org/10.1002/nau.24038
        • Coyne KS
        • Thompson CL
        • Lai JS
        • et al.
        An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF.
        Neurourol Urodyn. 2015; 34 (2015/03/19): 255-263https://doi.org/10.1002/nau.22559
        • Yalcin I
        • Bump RC
        Validation of two global impression questionnaires for incontinence.
        Am J Obstet Gynecol. 2003; 189 (2003/07/16): 98-101https://doi.org/10.1067/mob.2003.379
        • Coyne KS
        • Matza LS
        • Thompson CL
        • et al.
        Determining the importance of change in the overactive bladder questionnaire.
        J Urol. 2006; 176: 627-632
        • Sirls ER
        • Killinger KA
        • Boura JA
        • et al.
        Percutaneous tibial nerve stimulation in the office setting: real-world experience of over 100 patients.
        Urology. 2018; 113 (2017/12/03): 34-39https://doi.org/10.1016/j.urology.2017.11.026
        • Jung CE
        • Menefee SA
        • Diwadkar GB.
        Percutaneous tibial nerve stimulation maintenance therapy for overactive bladder in women: long-term success rates and adherence.
        Int Urogynecol J. 2020; (2020/06/24)https://doi.org/10.1007/s00192-020-04325-1
        • Amundsen CL
        • Richter HE
        • Menefee SA
        • et al.
        OnabotulinumtoxinA vs Sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial.
        JAMA. 2016; 316 (2016/10/05): 1366-1374https://doi.org/10.1001/jama.2016.14617
        • Srikrishna S
        • Robinson D
        • Cardozo L
        Validation of the patient global impression of improvement (PGI-I) for urogenital prolapse.
        Int Urogynecol J. 2010; 21 (2009/12/17): 523-528https://doi.org/10.1007/s00192-009-1069-5
        • Tincello DG
        • Owen RK
        • Slack MC
        • et al.
        Validation of the Patient Global Impression scales for use in detrusor overactivity: secondary analysis of the RELAX study.
        BJOG. 2013; 120 (2012/11/30): 212-216https://doi.org/10.1111/1471-0528.12069
        • Jung CE
        • Menefee SA
        • Diwadkar GB.
        8 versus 12 weeks of percutaneous tibial nerve stimulation and response predictors for overactive bladder.
        Int Urogynecol J. 2020; 31 (2020/01/14): 905-914https://doi.org/10.1007/s00192-019-04191-6
        • Iyer S
        • Laus K
        • Rugino A
        • et al.
        Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder.
        Int Urogynecol J. 2019; 30 (2018/11/24): 1253-1259https://doi.org/10.1007/s00192-018-3822-0
        • Rostaminia G
        • Chang C
        • Pincus JB
        • et al.
        Predictors of successful percutaneous tibial nerve stimulation (PTNS) in the treatment of overactive bladder syndrome.
        Int Urogynecol J. 2018; (2018/12/01)https://doi.org/10.1007/s00192-018-3834-9
        • MacDiarmid SA
        • Peters KM
        • Shobeiri SA
        • et al.
        Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder.
        J Urol. 2010; 183 (2009/11/17): 234-240https://doi.org/10.1016/j.juro.2009.08.160
        • Kobashi K
        • Nitti V
        • Margolis E
        • et al.
        A prospective study to evaluate efficacy using the nuro percutaneous tibial neuromodulation system in drug-naive patients with overactive bladder syndrome.
        Urology. 2019; 131 (2019/06/15): 77-82https://doi.org/10.1016/j.urology.2019.06.002